Keylika Analysis
What is Keylika?
Keylika develops innovative transdermal drug delivery systems, focusing on a skin patch for treating iron deficiency anemia, combining oral and IV iron benefits without side effects.
Founded
2022
Company Stage
Pre-Seed
Investors
- Y Combinator
- Fundament
YC Batch
S22
Product Features & Capabilities
- Custom transdermal iron patch (NistuFe) for iron deficiency anemia, new molecular entity (KYLK01), small molecule (< 500 Da), better absorption, no gastrointestinal side effects, higher bioavailability, self-administrable, low risk, NistuHeal skin cream solution.
Who are the founders of Keylika
BP
Buddhadev P. Chaudhuri
CEO & Co-Founder
FC
Frederik Ceyssens
CTO & Co-Founder
